MDCX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$4.50median target· current $0.16 (+2780.9%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
1 article · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-2.260.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$10.9MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 11.97
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -7446.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- -0.48
Last earnings
Aug 12, 2026 · Estimate $-0.14 · Reported $-0.21
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Medicus Pharma Ltd. Common Stock
Company profileMedicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. The company is headquartered in West Conshohocken, Pennsylvania.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 300 CONSHOHOCKEN STATE ROAD, WEST CONSHOHOCKEN, PA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$10.9M
Shares outstanding$71.7M
52W high$3.05
52W low$0.14
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent